Awful Consequence of Asthma on COVID-19
asthma and COVID-19
Sažetak
Background: Asthma is one of the most common chronic respiratory diseases in the world with the most frequent cause for hospitalization and emergency cases. Respiratory viruses are the most triggering cause.
Aim of the study: Assessment of the role of virus infections especially COVID-19 in the pathogenesis of asthma initiation and exacerbations.
Patients and methods: Electronic search was done for the manuscripts dealing with asthma as a risk factor for complications after COVID-19 infection. The outcomes were titles, materials, methods, and classified studies as related or not related for the review study. 300 publications were identified and only ten studies were selected for analysis. Seven studies were review, one retrospective, one longitudinal Cohort study, and one letter to the editor.
Results: The included literature have highlighted the different effect of asthma on COVID-19 progression, asthma may be trigger by COVID-19 viruses and asthmatic patient with COVID-19 should not stop biologic therapy to COVID-19 strategies as immunity boosters against infection. Others suggest that asthma does not appear to be a significant risk factor for developing severe COVID-19 requiring hospitalization or intubation.
Conclusions: Asthma is considered a comorbidity factor and depends on the type of asthma may be at high risk of developing complications and mortality when infected with COVID-19.
Reference
1. Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015 ;5 Suppl 1:S2-6.
2. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015 ;5 Suppl 1:S7-10.
3. O'Toole J, Mikulic L, Kaminsky DA. Epidemiology and Pulmonary Physiology of Severe Asthma. Immunol Allergy Clin North Am. 2016 ;36:425-38.
4. Toskala E, Kennedy DW. Asthma risk factors. Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1(Suppl 1):S11-6.
5. Tan J, Bernstein JA. Occupational asthma: an overview. Curr Allergy Asthma Rep. 2014;431:1–7.
6. Wu TD, Brigham EP, McCormack MC. Asthma in the Primary Care Setting. Med Clin North Am. 2019 ;103:435-452.
7. Al-Karkhy M, Nema M, Abdullah S. Correlation of Prostaglandin D2 with disease severity of adult asthma. J Fac Med Bagdad .2019 ;61:3-4.
8. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol;2017;140:895–906.
9. Al-Zaidi M, Kadhim H, Ahmed Shemran H. The possible association between Chlamydia pneumoniae infection and asthma. J Fac Med Bagdad. 2010 ;52:318-319.
10. Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5:918-927.
11. Sarıoğlu N. Asthma and COVID-19: What do we know? Tuberk Toraks. 2020;68:141-147.
12. Galib B. SARS-CoV-2(COVID-19). J Fac Med Bagdad. 2020;61:91-93.
13. Taher, T., Sarray, F., Farhan Al-Badri, S., & Ghazi, H. Comorbidity and Risk Factors for COVID-19 Confirmed Patients in Wasit Province, IRAQ. AL-Kindy College Medical Journal. 2020; 16(supplement): 1-8.
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009 ;62:e1-34.
15. Johnston SL. Asthma and COVID-19: Is asthma a risk factor for severe outcomes? Allergy. 2020 Jul;75(7):1543-1545.
16. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, Mai Q, Yeh C, Muhammad LN, Harris KE, Bochner BS, Grammer LC, Greenberger PA, Kalhan R, Kuang FL, Saltoun CA, Schleimer RP, Stevens WW, Peters AT. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4.
17. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, Caminati M, Canonica GW, Carr T, Chupp G, Corren J, Dávila I, Park HS, Hanania NA, Rosenwasser L, Sánchez-Borges M, Virchow JC, Yáñez A, Bernstein JA, Caraballo L, Chang YS, Chikhladze M, Fiocchi A, González-Diaz SN, Tanno LK, Levin M, Ortega-Martell JA, Passalacqua G, Peden DB, Rouadi PW, Sublett JL, Wong GWK, Bleecker ER. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020;13:100126.
18. Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. Int Arch Allergy Immunol. 2020;181:680-688.
19. Abrams EM, Jong GWG and Yang CL. Practice five things to know about asthma and covid-19.CMAJ. 2020;192:E551.
20. Wang JY, Pawankar R, Tsai HJ, Wu LS, Kuo WS. COVID-19 and asthma, the good or the bad? Allergy. 2020 3:10.1111/all.14480.
21. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90.
22. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol. 2020 Aug;59(1):78-88.
23. Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, Kinton J, Inada-Kim M, Hobbs FDR, Dennison P. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med. 2020 Sep 3:bmjebm-2020-111506.
24. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc. 2020 Dec;17(12):1645-1648.
25. Bochkov YA, Gern JE . Rhinoviruses and their receptors:implications for allergic disease. Curr Allergy Asthma Rep.2016; 16:30.
26. Nakagome K, Bochkov YA, Ashraf S, Brockman-Schneider RA, Evans MD, Pasic TR, Gern JE .Effects of rhinovirus species on viral replication and cytokine production. J Allergy Clin Immunol.2014; 134:332–341.
27. Jackson DJ,Makrinioti H, Rana BM, ShamjiBW, Trujillo-Torralbo MB, Footitt J, Del-Rosario J, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type 2 inflammation during rhinovirusinduced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014; 190:1373–1382.
28. Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M,Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014; 6:256ra134.
29. 64. Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, Denney L, Bossley CJ, Oates T, Walker SA, Bush A, Lloyd CM. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol. 2013;132:676–685.
30. Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, Gangnon RE, Gill MA, Gern JE, Lemanske RF, Jackson DJ. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012; 130:489–495.
31. Daccord C, Touilloux B, Von Garnier C. Asthma and COPD management during the COVID-19 pandemic. Rev Med Suisse.2020;16:933-938.
32. Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY, Xu SP, Wang GP, Guo CL, Deng YK, Wang ZC, Ma J, Pan L, Liao B, Du ZH, Feng QM, Liu Y, Xie JG, Liu Z. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021;76:483-496.
33. Wang Y, Chen J, Chen W, Liu L, Dong M, Ji J, Hu D, Zhang N. Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol. 2021;182:76-82.
34. Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, Cho JH, Kim HJ, Lee JH, Park JW, Park HJ. Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19. Eur Respir J. 2021 Feb 4:2002226.
35. Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9:684-692.e1.
36. Wakabayashi M, Pawankar R, Narazaki H, Ueda T, Itabashi T. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions. Curr Opin Allergy Clin Immunol. 2021 ;21:1-7.
2. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015 ;5 Suppl 1:S7-10.
3. O'Toole J, Mikulic L, Kaminsky DA. Epidemiology and Pulmonary Physiology of Severe Asthma. Immunol Allergy Clin North Am. 2016 ;36:425-38.
4. Toskala E, Kennedy DW. Asthma risk factors. Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1(Suppl 1):S11-6.
5. Tan J, Bernstein JA. Occupational asthma: an overview. Curr Allergy Asthma Rep. 2014;431:1–7.
6. Wu TD, Brigham EP, McCormack MC. Asthma in the Primary Care Setting. Med Clin North Am. 2019 ;103:435-452.
7. Al-Karkhy M, Nema M, Abdullah S. Correlation of Prostaglandin D2 with disease severity of adult asthma. J Fac Med Bagdad .2019 ;61:3-4.
8. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol;2017;140:895–906.
9. Al-Zaidi M, Kadhim H, Ahmed Shemran H. The possible association between Chlamydia pneumoniae infection and asthma. J Fac Med Bagdad. 2010 ;52:318-319.
10. Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5:918-927.
11. Sarıoğlu N. Asthma and COVID-19: What do we know? Tuberk Toraks. 2020;68:141-147.
12. Galib B. SARS-CoV-2(COVID-19). J Fac Med Bagdad. 2020;61:91-93.
13. Taher, T., Sarray, F., Farhan Al-Badri, S., & Ghazi, H. Comorbidity and Risk Factors for COVID-19 Confirmed Patients in Wasit Province, IRAQ. AL-Kindy College Medical Journal. 2020; 16(supplement): 1-8.
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009 ;62:e1-34.
15. Johnston SL. Asthma and COVID-19: Is asthma a risk factor for severe outcomes? Allergy. 2020 Jul;75(7):1543-1545.
16. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, Mai Q, Yeh C, Muhammad LN, Harris KE, Bochner BS, Grammer LC, Greenberger PA, Kalhan R, Kuang FL, Saltoun CA, Schleimer RP, Stevens WW, Peters AT. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4.
17. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, Caminati M, Canonica GW, Carr T, Chupp G, Corren J, Dávila I, Park HS, Hanania NA, Rosenwasser L, Sánchez-Borges M, Virchow JC, Yáñez A, Bernstein JA, Caraballo L, Chang YS, Chikhladze M, Fiocchi A, González-Diaz SN, Tanno LK, Levin M, Ortega-Martell JA, Passalacqua G, Peden DB, Rouadi PW, Sublett JL, Wong GWK, Bleecker ER. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020;13:100126.
18. Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. Int Arch Allergy Immunol. 2020;181:680-688.
19. Abrams EM, Jong GWG and Yang CL. Practice five things to know about asthma and covid-19.CMAJ. 2020;192:E551.
20. Wang JY, Pawankar R, Tsai HJ, Wu LS, Kuo WS. COVID-19 and asthma, the good or the bad? Allergy. 2020 3:10.1111/all.14480.
21. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020 Jul 1;202(1):83-90.
22. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol. 2020 Aug;59(1):78-88.
23. Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, Kinton J, Inada-Kim M, Hobbs FDR, Dennison P. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med. 2020 Sep 3:bmjebm-2020-111506.
24. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc. 2020 Dec;17(12):1645-1648.
25. Bochkov YA, Gern JE . Rhinoviruses and their receptors:implications for allergic disease. Curr Allergy Asthma Rep.2016; 16:30.
26. Nakagome K, Bochkov YA, Ashraf S, Brockman-Schneider RA, Evans MD, Pasic TR, Gern JE .Effects of rhinovirus species on viral replication and cytokine production. J Allergy Clin Immunol.2014; 134:332–341.
27. Jackson DJ,Makrinioti H, Rana BM, ShamjiBW, Trujillo-Torralbo MB, Footitt J, Del-Rosario J, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type 2 inflammation during rhinovirusinduced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014; 190:1373–1382.
28. Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M,Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014; 6:256ra134.
29. 64. Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, Denney L, Bossley CJ, Oates T, Walker SA, Bush A, Lloyd CM. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol. 2013;132:676–685.
30. Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, Gangnon RE, Gill MA, Gern JE, Lemanske RF, Jackson DJ. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012; 130:489–495.
31. Daccord C, Touilloux B, Von Garnier C. Asthma and COPD management during the COVID-19 pandemic. Rev Med Suisse.2020;16:933-938.
32. Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY, Xu SP, Wang GP, Guo CL, Deng YK, Wang ZC, Ma J, Pan L, Liao B, Du ZH, Feng QM, Liu Y, Xie JG, Liu Z. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021;76:483-496.
33. Wang Y, Chen J, Chen W, Liu L, Dong M, Ji J, Hu D, Zhang N. Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol. 2021;182:76-82.
34. Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, Cho JH, Kim HJ, Lee JH, Park JW, Park HJ. Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19. Eur Respir J. 2021 Feb 4:2002226.
35. Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9:684-692.e1.
36. Wakabayashi M, Pawankar R, Narazaki H, Ueda T, Itabashi T. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions. Curr Opin Allergy Clin Immunol. 2021 ;21:1-7.
Objavljeno
2025/12/21
Broj časopisa
Rubrika
Originalni rad / Original article